LifeCycle Pharma A/S (LCP) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for LCP's US patent application directed to LCP's fenofibrate tablet.

The patent application covers Fenoglide, a product for which LifeCycle Pharma has previously obtained US NDA approval and is now marketed in the US by Sciele Pharma, Inc. (a Shionogi company).

"This Notice of Allowance represents a strategically important accomplishment for LifeCycle Pharma and demonstrates the company's ability to obtain individual patents for products developed by Life Cycle Pharma that use its proprietary formulation technology. Our technology enables us to overcome two classic drug delivery challenges that often are in opposition, extended release and increased oral bioavailability. In addition, the technology can be implemented at commercial scale," said Dr. William J. Polvino, president and CEO of LifeCycle Pharma. "The U.S. marketing approval and new US patent Notice of Allowance validates that our innovative technology can provide patent-protected products to the market place. Upon issuance, the patent will support the ongoing sales of Fenoglide," added Dr Polvino.

Based in Horsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases.